Hemophilia Clinical Research Trials | CenterWatch
Mim8 data sees potential as once monthly treatment for haemophilia A - European Pharmaceutical Manufacturer
Novo makes a rare disease push | Evaluate
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates
Novo Nordisk prepares phase III trial of potential blockbuster drug — MedWatch
Novo Nordisk's hemophilia drug shows potential as once-monthly treatment — MedWatch
Study Set to Assess Mim8 Therapy in People With Hemophilia A
The Effect of rFVIIa and Mim8 Combination in Hemophilia A-like Blood - ISTH Congress Abstracts
ISTH 2022 – Novo moves forward with its Hemlibra rival | Evaluate
Mim8 does not affect FVIII function in hemophilia A - ISTH Congress Abstracts
A multiple ascending dose study of Mim8 in patients with severe haemophilia A with or without factor VIII inhibitors
A multiple ascending dose study of Mim8 in patients with severe hemophilia A with or without factor VIII inhibitors
Summer 2022 haemophilia trial update - European Pharmaceutical Review
Novo Nordisk gets CDSCO Panel nod to study NN0365-3769
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Mim8 data sees potential as once monthly treatment for haemophilia A - European Pharmaceutical Manufacturer
Emerging drugs for hemophilia A: insights into phase II and III clinical trials
Mim8 clinical development program: an overview of the FRONTIER studies
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Novo Nordisk: positivity for haemophilia treatment - Drug Discovery World (DDW)
Marianne Kjalke's research works | Novo Nordisk, Copenhagen and other places
